Evidence map›Paper›PMID 32872566›Full record

ArticleBioengineering (Basel, Switzerland)2020

Utilization of an Industry Byproduct,

Mishal Subhan, Rani Faryal, Ian Macreadie

Open access · goldAbstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Mishal SubhanDepartment of Microbiology, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Rani FaryalDepartment of Microbiology, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Ian MacreadieSchool of Science, RMIT University, Bundoora, Victoria 3083, Australia.
Quaid-i-Azam University · PKRMIT University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to its ability to lower cholesterol levels, simvastatin is a leading drug for the prevention of strokes and heart disease: it also lowers the incidence of neurodegenerative diseases. Simvastatin is made from lovastatin, a precursor produced by the industrial fungus,

Indexed as

Aspergillus terreuseucalyptusfermentationlovastatinSmFSSF

Identifiers

PMID32872566
PMCPMC7552682
OpenAlexW3082163557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.